Opinion

Video

ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Author(s):

Jason Porter, MD

Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.

Video content above is prompted by the following questions:

  1. How do these four trials address the unmet needs of patients with NSCLC?
  2. After the presentation of advancements in NSCLC research at ASCO, how do you envision the future of personalized medicine in this disease?
  3. Please discuss any other data in NSCLC released at ASCO 2024 that you find noteworthy to share with colleagues.
  4. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of NSCLC? What can we look forward to through the end of the year and beyond?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Related Content
AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
July 22nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD
There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.
AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
July 15th 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.
Lung cancer | Image credit: appledesign - stock.adobe.com
July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).
IV chemotherapy-Aidman-stock.adobe.com
July 11th 2025

Patients With Advanced NSCLC Face Critical Treatment Gaps

Giuliana Grossi
New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.
FDA Approved
July 7th 2025

FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

Julia Bonavitacola
The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo